// App-Quantinova.ai

2838 : Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model

Researchers

Presenter

  • Paul Koller

Principal Investigators

  • Karine Harutyunyan

  • Antonio Cavazos

  • Natalia Baran

  • Saradhi Mallampati

  • Renee Chin

  • Zhou Jiang

  • Heng-Huan Lee

  • Michael Curran

  • Mien-Chie Hung

  • Marina Konopleva

Medical Centers

  • Department of Hematology/HCT, City of Hope, Duarte, CA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Hematopathology,The University of Texas M.D. Anderson Cancer Center,Houston,United States

  • Graduate School of Biomedical Science, University of Texas at Houston Health Science Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • China Medical University Hospital, Taichung, Taiwan

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Acute myelocytic leukemia

  • Acute Leukemia

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Adenomatous Polyposis Coli

  • Breakpoint Cluster Region

  • Ph chromosome

  • Cluster of Differentiation 11c

  • tumor-infiltrating lymphocytes

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • dasatinib

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT04284202

  • NCT03516279

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved